-
Mashup Score: 0Potential targeted therapy for pediatric brain cancer identified by Dana-Farber/Boston Children's team | Dana-Farber Cancer Institute - 1 month(s) ago
An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric and young patients with a form of high-grade glioma. They found that the drug, already FDA-approved for certain adult cancers, was generally safe and resulted in tumor reduction visible on brain scans, as well as clinical improvement, in 3 out of 7 patients.
Source: www.dana-farber.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1
Childhood cancer survivors in Europe exhibited higher risk for suicidal ideation than the general population, according to results of a systematic review and meta-analysis.This finding highlights “the psychological impact of cancer,” researcher Cyrus Su Hui Ho, MBBS, PhD, MSc, assistant professor and senior consultant psychiatrist in the department of psychological medicine at
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet-
Childhood cancer survivors in Europe exhibited higher risk for suicidal ideation than the general population, according to data in @JAMANetworkOpen. Risk is particularly elevated among males and those in poor physical health. #ChildhoodCancer #Suicide https://t.co/5qOA3JXFwv
-
-
Mashup Score: 0Clinical Scenario 1: A HER2+ mBC Patient With Trastuzumab Deruxtecan With Brain Mets - 1 month(s) ago
Panelists discuss how trastuzumab deruxtecan (Enhertu) is used to treat HER2-positive metastatic breast cancer with brain metastases, emphasizing its effectiveness in achieving systemic tumor reduction and CNS lesion stabilization while exploring treatment challenges and emerging strategies in this patient population.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Hear Timothy Pluard, MD and Ruta Rao, MD discuss how trastuzumab deruxtecan is used to treat HER2-positive metastatic breast cancer with brain metastases. Watch more here: https://t.co/td46hswtbt
-
-
Mashup Score: 2Peritumoral edema resolves infrequently in surgically treated patients with intracranial meningioma– a retrospective study of 279 meningioma patients - 1 month(s) ago
Journal of Neuro-Oncology – The resolution of peritumoral brain edema (PTBE) following surgery for intracranial meningioma (IM) is poorly understood. We hypothesized that PTBE represents a more…
Source: link.springer.comCategories: General Medicine News, Oncologists1Tweet-
Laajava et al. showed that peritumoral edema often persists after meningioma resection. Considerable resolution occurs in many cases, though complete resolution is rare, hinting at gliosis as a lingering factor.#JNO Read more:https://t.co/Mx24vYMkEy https://t.co/HpfpLsoHDE
-
-
Mashup Score: 2
ASTRO’s weekly member newsletter for the week of March 17: ROCR Act reintroduced, Don’t miss 2025 Refresher, Leadership Pathway Program Awardees
Source: www.astro.orgCategories: General Medicine News, Oncologists1Tweet-
New in this week's ASTROgram ➡️ ROCR Act reintroduced, Don’t miss 2025 Refresher, Leadership Pathway Program Awardees https://t.co/wIZ7N9Cvhq https://t.co/JwlaF0TBA4
-
-
Mashup Score: 0Genomic Summary Results | EGRP/DCCPS/NCI/NIH - 1 month(s) ago
Resources for investigators to find and make publicly available genomic summary results (GSR) data from cancer research studies.
Source: epi.grants.cancer.govCategories: General Medicine News, Oncologists1Tweet-
Cancer researchers: Did you know that many research questions do not require individual-level data and can be addressed using genomic summary results (GSR)? Learn more about finding and sharing GSR data. https://t.co/bs5Pc31PY4 #data #OncTwitter https://t.co/szRewTH7EW
-
-
Mashup Score: 0Artificial Intelligence (AI) Model, “HistoTME,” Aids in Predicting Response to Immunotherapy | CBIIT - 1 month(s) ago
NCI researchers debuted a new deep learning model that could help you decipher the cancer tumor’s microenvironment. The model holds a lot of promise for predicting which patients are most likely to benefit from checkpoint inhibitors.
Source: datascience.cancer.govCategories: General Medicine News, Oncologists1Tweet-
NCI researchers have developed a #DeepLearning model that could provide information about the tumor microenvironment and may aid in predicting the response to cancer #immunotherapy. The artificial intelligence (#AI) model is called HistoTME. https://t.co/WUuFZBy0cq 👀 https://t.co/Qu0FjNDwpD
-
-
Mashup Score: 0
Panelists discuss how the NCCN guidelines for risk stratification in HR+/HER2- early-stage breast cancer inform clinical decision-making, with an emphasis on biomarker testing, the use of tools like RSClin N+, and the evolving role of CDK4/6 inhibitors and adjuvant therapies. They also address challenges in risk assessment and the integration of newer treatment strategies, such as CDK4/6 inhibitors and PARP inhibitors in the early-stage setting.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Tune in to watch a panel lead by @dradityabardia discuss how the NCCN guidelines for risk stratification in HR+/HER2- early-stage breast cancer inform clinical decision-making, with an emphasis on biomarker testing. https://t.co/he4iLL2d5H
-
-
Mashup Score: 0Automated Follow-up Alerts Pharmacists to Cancer Patients’ Needs - 1 month(s) ago
Early automated follow-up of cancer patients can help pharmacists more efficiently manage side effects of oral oncolytic medications, according to data presented at the ASHP Midyear 2024 Clinical Meeting & Exhibition.
Source: www.clinicaloncology.comCategories: General Medicine News, Oncologists1Tweet-
Early automated follow-up of cancer patients can help pharmacists more efficiently manage side effects of oral oncolytic medications, according to data presented at the ASHP Midyear 2024 Clinical Meeting & Exhibition. https://t.co/GIAEpIJJku https://t.co/ogE6Hx2ubq
-
-
Mashup Score: 0Keytruda Receives Traditional Approval for Some Patients With HER2-Positive Gastric or GEJ Adenocarcinoma - 1 month(s) ago
The FDA has granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express programmed death ligand-1 (PD-L1) (combined positive score [CPS] ≥1).
Source: www.clinicaloncology.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemo for some locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma. https://t.co/2tTYqijLGO https://t.co/hxmMkuyvwd
-
Researchers from the lab of Mariella Filbin, MD, PhD, in collaboration with @umichmedicine and the Medical University of Vienna, explore a potential new use for Avapritinib in treating aggressive gliomas. Learn more: https://t.co/oNl3Stk0ae